LTI 03
Alternative Names: Caveolin-1 scaffold protein-derived 7-amino acid peptide; Caveolin-1 scaffolding protein derived peptide; CSP7; LTI-03Latest Information Update: 22 Sep 2025
At a glance
- Originator Lung Therapeutics; University of Texas at Tyler
- Developer Rein Therapeutics; University of Texas at Tyler
- Class Alcohols; Amides; Amino acids; Antifibrotics; Benzene derivatives; Carboxylic acids; Peptides
- Mechanism of Action Caveolin 1 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis
Most Recent Events
- 22 Sep 2025 Chemical structure information added.
- 17 Sep 2025 Pharmacodynamics data from a preclinical trial in idiopathic pulmonary fibrosis released by Rein Therapeutics
- 28 Aug 2025 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(In volunteers) in United Kingdom (Inhalation, Powder)